Antibody Information

General Information of This Antibody
Antibody ID
ANI0BTNLJ
Antibody Name
IMAB362
Organization
Ganymed Pharmaceuticals AG
Indication
Pancreatic cancer; Gastric cancer
Synonyms
Zolbetuximab
   Click to Show/Hide
Antibody Type
Monoclonal antibody (mAb)
Antibody Subtype
Chimeric IgG1-kappa
Antigen Name
Claudin-18.2 (CLDN18.2)
  Antigen Info 
ChEMBI ID
CHEMBL2109427
DrugBank ID
DB15118
Click to Show/Hide the Sequence Information of This Antibody
Heavy Chain Sequence
QVQLQQPGAELVRPGASVKLSCKASGYTFTSYWINWVKQRPGQGLEWIGNIYPSDSYTNY
NQKFKDKATLTVDKSSSTAYMQLSSPTSEDSAVYYCTRSWRGNSFDYWGQGTTLTVSSAS
TKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGL
YSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPS
VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNST
YRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMT
KNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQ
GNVFSCSVMHEALHNHYTQKSLSLSPGK
    Click to Show/Hide
Heavy Chain Varible Domain
QVQLQQPGAELVRPGASVKLSCKASGYTFTSYWINWVKQRPGQGLEWIGNIYPSDSYTNY
NQKFKDKATLTVDKSSSTAYMQLSSPTSEDSAVYYCTRSWRGNSFDYWGQGTTLTVSS
    Click to Show/Hide
Heavy Chain Constant Domain 1
ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS
GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRV
    Click to Show/Hide
Heavy Chain Constant Domain 2
APELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTK
PREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK
    Click to Show/Hide
Heavy Chain Constant Domain 3
GQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDS
DGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
    Click to Show/Hide
Heavy Chain Hinge Region
EPKSCDKTHTCPPCP
    Click to Show/Hide
Heavy Chain CDR 1
GYTFTSYW
    Click to Show/Hide
Heavy Chain CDR 2
IYPSDSYT
    Click to Show/Hide
Heavy Chain CDR 3
TRSWRGNSFDY
    Click to Show/Hide
Light Chain Sequence
DIVMTQSPSSLTVTAGEKVTMSCKSSQSLLNSGNQKNYLTWYQQKPGQPPKLLIYWASTR
ESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYYCQNDYSYPFTFGSGTKLEIKRTVAAPS
VFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYS
LSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
    Click to Show/Hide
Light Chain Varible Domain
DIVMTQSPSSLTVTAGEKVTMSCKSSQSLLNSGNQKNYLTWYQQKPGQPPKLLIYWASTR
ESGVPDRFTGSGSGTDFTLTISSVQAEDLAVYYCQNDYSYPFTFGSGTKLEIK
    Click to Show/Hide
Light Chain Constant Domain
RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD
SKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
    Click to Show/Hide
Light Chain CDR 1
QSLLNSGNQKNY
    Click to Show/Hide
Light Chain CDR 2
WAS
    Click to Show/Hide
Light Chain CDR 3
QNDYSYPFT
    Click to Show/Hide
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
IMAB362-MC-Val-Cit-PAB-MMAE [Investigative]
 ADC Info 
Discovered Using Patient-derived Xenograft Model
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 63.30% Positive CLDN18.2 expression (CLDN18.2 +++/++)
Method Description
Conjugates of the exemplary antibodies were tested using an established PDX model of pancreatic cancer cell implanted subcutaneous into SCID mice. Mice were randomized by body weight into treatment groups and treated once post cell inoculation with 5 mg/kg of one of the conjugates listed above or with PBS only.
In Vivo Model Pancreatic cancer PDX model
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
501 ng/mL
Positive CLDN18.2 expression (CLDN18.2 +++/++)
Method Description
Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model Gastric tubular adenocarcinoma NCI-N87 cells CVCL_1603
IMAB362-DM4 [Investigative]
 ADC Info 
Revealed Based on the Cell Line Data
Click To Hide/Show 6 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC
Efficacy Data Half Maximal Effective Concentration (EC50)
155 ng/ml
High CLDN18.2 expression (CLDN18.2 +++)
Method Description
A Cell line test on NUGC-4 10cF7-5 sort 3A
In Vitro Model Gastric adenocarcinoma NUGC-4 10cF7-5 sort 3a cells CVCL_3082
Experiment 2 Reporting the Activity Date of This ADC
Efficacy Data Half Maximal Effective Concentration (EC50)
372 ng/ml
High CLDN18.2 expression (CLDN18.2 +++)
Method Description
A Cell line test on NUGC-4 10cE8
In Vitro Model Gastric adenocarcinoma NUGC-4 10cE8 cells CVCL_3082
Experiment 3 Reporting the Activity Date of This ADC
Efficacy Data Half Maximal Effective Concentration (EC50)
2600 ng/ml
High CLDN18.2 expression (CLDN18.2 +++)
Method Description
A Cell line test on NUGC-4 10cF7-5 so1t 33
In Vitro Model Gastric adenocarcinoma NUGC-4 10cF7-5 so1t 33 cells CVCL_3082
Experiment 4 Reporting the Activity Date of This ADC
Efficacy Data Half Maximal Effective Concentration (EC50)
3046 ng/ml
High CLDN18.2 expression (CLDN18.2 +++)
Method Description
A Cell line test on NUGC-4 10cE8
In Vitro Model Gastric adenocarcinoma NUGC-4 10cE8 cells CVCL_3082
Experiment 5 Reporting the Activity Date of This ADC
Efficacy Data Half Maximal Effective Concentration (EC50)
3909 ng/ml
High CLDN18.2 expression (CLDN18.2 +++)
Method Description
A Cell line test on NUGC-4 10cF7-5 so1t 33
In Vitro Model Gastric adenocarcinoma NUGC-4 10cF7-5 so1t 33 cells CVCL_3082
Experiment 6 Reporting the Activity Date of This ADC
Efficacy Data Half Maximal Effective Concentration (EC50)
7487 ng/ml
High CLDN18.2 expression (CLDN18.2 +++)
Method Description
A Cell line test on NUGC-4 10cE8
In Vitro Model Gastric adenocarcinoma NUGC-4 10cE8 cells CVCL_3082
IMAB362-vCMMAE [Investigative]
 ADC Info 
Revealed Based on the Cell Line Data
Click To Hide/Show 6 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC
Efficacy Data Half Maximal Effective Concentration (EC50)
338 ng/ml
High CLDN18.2 expression (CLDN18.2 +++)
Method Description
A Cell line test on NUGC-4 10cF7-5 sort 3A
In Vitro Model Gastric adenocarcinoma NUGC-4 10cF7-5 sort 3a cells CVCL_3082
Experiment 2 Reporting the Activity Date of This ADC
Efficacy Data Half Maximal Effective Concentration (EC50)
631 ng/ml
High CLDN18.2 expression (CLDN18.2 +++)
Method Description
A Cell line test on NUGC-4 10cE8
In Vitro Model Gastric adenocarcinoma NUGC-4 10cE8 cells CVCL_3082
Experiment 3 Reporting the Activity Date of This ADC
Efficacy Data Half Maximal Effective Concentration (EC50)
2520 ng/ml
High CLDN18.2 expression (CLDN18.2 +++)
Method Description
A Cell line test on NUGC-4 10cF7-5 so1t 33
In Vitro Model Gastric adenocarcinoma NUGC-4 10cF7-5 so1t 33 cells CVCL_3082
Experiment 4 Reporting the Activity Date of This ADC
Efficacy Data Half Maximal Effective Concentration (EC50)
2826 ng/ml
High CLDN18.2 expression (CLDN18.2 +++)
Method Description
A Cell line test on NUGC-4 10cE8
In Vitro Model Gastric adenocarcinoma NUGC-4 10cE8 cells CVCL_3082
Experiment 5 Reporting the Activity Date of This ADC
Efficacy Data Half Maximal Effective Concentration (EC50)
4049 ng/ml
High CLDN18.2 expression (CLDN18.2 +++)
Method Description
A Cell line test on NUGC-4 10cF7-5 so1t 33
In Vitro Model Gastric adenocarcinoma NUGC-4 10cF7-5 so1t 33 cells CVCL_3082
Experiment 6 Reporting the Activity Date of This ADC
Efficacy Data Half Maximal Effective Concentration (EC50)
5464 ng/ml
High CLDN18.2 expression (CLDN18.2 +++)
Method Description
A Cell line test on NUGC-4 10cE8
In Vitro Model Gastric adenocarcinoma NUGC-4 10cE8 cells CVCL_3082
IMAB362-LC-G2-PNU [Investigative]
 ADC Info 
Revealed Based on the Cell Line Data
Click To Hide/Show 2 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [2]
Efficacy Data Half Maximal Effective Concentration (EC50)
0.6779 ug/ml
High Claudin-18.2 expression (Claudin-18.2 +++)
Method Description
A Cell line test on HEK293T
In Vitro Model Normal HEK293T cells CVCL_0063
Experiment 2 Reporting the Activity Date of This ADC [2]
Efficacy Data Half Maximal Effective Concentration (EC50)
0.6779 ug/ml
High Claudin-18.2 expression (Claudin-18.2 +++)
Method Description
A Cell line test on HEK293T
In Vitro Model Normal HEK293T cells CVCL_0063
References
Ref 1 Anti-claudin 18.2 antibody and antibody-drug conjugate thereof; 2022-11-17.
Ref 2 Tumor-specific claudin 18.2 antibody-drug complex